Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3

I read it the same way. Also note that they say "majority of initial patients completing dosages under
the trial due to complete this quarter" - they are not committing to the report being released.

While the delays are frustrating, hopefully some of the longer durations of testing gives a longer timeline of data points.

Collab and partnering negotiations are progressing - so its all bubbling away in the background, once the trial results are released there could be some deals....

I'll keep accumulating on weakness, pretty full on these now though.